EMA’s PRIME Is Driving Innovation, But Too Early To Tell If Drugs Will Reach Patients Faster

With just three marketing applications filed, the European Medicines Agency says it is too soon to say whether PRIME, its priority medicines scheme, is meeting its objective. The agency is satisfied, though, that the scheme has started to drive innovation.

Woman doctor use tablet . Mixed media
The EMA says its PRIME scheme is driving innovation • Source: Shutterstock

More from Market Access

More from Pink Sheet